Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type Journal Article
PMID (41367868)
Authors Liu L, Zhu X, Guo Y, Tang M, Zhou W, Chen B
Title Dabrafenib plus trametinib in an elderly patient with BRAF V600E-mutant advanced pancreatic adenocarcinoma: A case report.
Journal Vol Issue Date Pages Journal Short Title
Frontiers in oncology 15 2025 1687796 Front Oncol
URL
Abstract Text Despite the success of anti-BRAF therapy in melanoma, data from randomized clinical trials are lacking for targeted therapy against BRAF mutations-typically the V600E variant-in pancreatic adenocarcinoma, which is associated with a poor prognosis under traditional cytotoxic chemotherapy. Here, we report a case of an elderly patient with advanced pancreatic adenocarcinoma harboring a BRAF V600E mutation who received low-dose dabrafenib and trametinib and achieved satisfactory clinical outcomes. We describe a 78-year-old female with BRAF V600E-mutant pancreatic adenocarcinoma. The patient was diagnosed with AJCC clinical stage IV (cT3N2M1) pancreatic adenocarcinoma and she declined chemotherapy because of her advanced age. Owing to the BRAF V600E mutation, the patient was started on combined BRAF- and MEK inhibitors (dabrafenib/trametinib). CT scans showed PR on 31 December 31, 2024, and repeated CT scans showed SD on May 2025. At the time of drafting this report, the patient had achieved 8 months of PFS. This case suggests that dose-adjusted dabrafenib combined with trametinib might be a potentially effective treatment strategy for elderly patients with advanced pancreatic adenocarcinoma harboring BRAF V600E mutations.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF V600E pancreatic ductal adenocarcinoma predicted - sensitive Dabrafenib + Trametinib Case Reports/Case Series Actionable In a clinical case study, combination treatment with Tafinlar (dabrafenib) and Mekinist (trametinib) led to a partial response and a progression-free survival of 8 months in an elderly patient with metastatic pancreatic ductal adenocarcinoma harboring BRAF V600E (PMID: 41367868). 41367868